We are live on ! Find out more
DMK

David M. Knott Portfolio holdings

AUM $275M
1-Year Est. Return 59.23%
This Fund
S&P 500
This Quarter Est. Return
+6.72%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$281M
AUM Growth
+$47.6M
Cap. Flow
+$23.4M
Cap. Flow %
8.3%
Top 10 Hldgs %
45.9%
Holding
164
New
35
Increased
26
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MITAU
Coliseum Acquisition Corp. Unit
MITAU
+$14.7M
2
PSTH
Pershing Square Tontine Holdings, Ltd.
PSTH
+$6.6M
3
FAZE
FaZe Holdings Inc. Common Stock
FAZE
+$5.13M
4
TWLV
Twelve Seas Investment Company II Class A Common Stock
TWLV
+$4.99M
5
GLHA
Glass Houses Acquisition Corp. Class A common stock
GLHA
+$4.83M

Top Sells

Rank Stock Value
1
AGAC.U
African Gold Acquisition Corp Units
AGAC.U
+$6.11M
2
TWLVU
Twelve Seas Investment Company II Unit
TWLVU
+$5.07M
3
GLHAU
Glass Houses Acquisition Corp. Unit
GLHAU
+$5.01M
4
LOKM.U
Live Oak Mobility Acquisition Corp. Units, each consisting of one share of Class A common stock, and one-fifth of one warrant
LOKM.U
+$3.59M
5
DOMA
Doma Holdings, Inc.
DOMA
+$2.52M

Sector Composition

Rank Sector Weight
1 Financials 27.9%
2 Healthcare 23.27%
3 Miscellaneous 14.09%
4 Materials 10.3%
5 Communication Services 8.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3M 1.06%
32,000
-8,614
-21% -$793K
BMY icon
27
Bristol-Myers Squibb
BMY
$136B
$2.9M 1.03%
43,409
-8,000
-16% -$522K
GLHAW
28
DELISTED
Glass Houses Acquisition Corp. Warrant
GLHAW
$2.88M 1.02%
+250,000
New +$220K
JPM icon
29
JPMorgan Chase
JPM
$951B
$2.83M 1%
18,170
+2,700
+17% +$424K
UTHR icon
30
United Therapeutics
UTHR
$22.1B
$2.75M 0.98%
15,300
+800
+6% +$152K
XENE icon
31
Xenon Pharmaceuticals
XENE
$5.81B
$2.62M 0.93%
140,551
-3,550
-2% -$65.4K
BRSL
32
Brightstar Lottery PLC
BRSL
$2.11B
$2.58M 0.92%
107,500
– –
EIGR
33
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.44M 0.87%
9,552
+334
+4% +$83.4K
AB icon
34
AllianceBernstein
AB
$3.43B
$2.35M 0.84%
50,500
– –
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
$2.15M 0.77%
124,688
+7,000
+6% +$129K
AUPH icon
36
Aurinia Pharmaceuticals
AUPH
$2.17B
$2.14M 0.76%
164,840
+10,000
+6% +$127K
HZON
37
DELISTED
Horizon Acquisition Corporation II
HZON
$2.09M 0.74%
+210,100
New +$2.1M
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$2.05M 0.73%
304,922
+32,077
+12% +$255K
TWLVW
39
DELISTED
Twelve Seas Investment Company II Warrant
TWLVW
$1.98M 0.7%
+171,666
New +$125K
TGTX icon
40
TG Therapeutics
TGTX
$8.26B
$1.95M 0.69%
50,373
-1,600
-3% -$62.8K
PMGM
41
DELISTED
Priveterra Acquisition Corp. II Class A Common Stock
PMGM
$1.94M 0.69%
200,000
– –
TRIL
42
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.93M 0.68%
198,699
– –
KAIRW
43
DELISTED
Kairos Acquisition Corp. Warrant
KAIRW
$1.69M 0.6%
146,528
+15,841
+12% +$11.7K
ASLN
44
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.58M 0.56%
11,955
+1,020
+9% +$128K
MRNS
45
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.46M 0.52%
81,166
+20,900
+35% +$336K
QURE icon
46
uniQure
QURE
$3.38B
$1.44M 0.51%
46,766
+5,000
+12% +$168K
CHRS icon
47
Coherus Oncology
CHRS
$218M
$1.38M 0.49%
99,655
– –
QUOT
48
DELISTED
Quotient Technology Inc
QUOT
$1.35M 0.48%
125,000
+75,000
+150% +$1M
INSE icon
49
Inspired Entertainment
INSE
$156M
$1.27M 0.45%
+100,000
New +$1.01M
VKTX icon
50
Viking Therapeutics
VKTX
$3.75B
$1.25M 0.44%
208,102
– –
1
2
3 4 5

Similar funds

FA
FMA Advisory Harrisburg, Pennsylvania $268M AUM 30.8% 1-Year Est. Return
KCP
KDI Capital Partners Raleigh, North Carolina $290M AUM 26.07% 1-Year Est. Return
HCIA
Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return
ISG
Investment Security Group Denver, Colorado $252M AUM 28.26% 1-Year Est. Return
TPCM
Three Peaks Capital Management Castle Rock, Colorado $301M AUM 43.39% 1-Year Est. Return
DCM
DeGreen Capital Management Scottsdale, Arizona $301M AUM 17.24% 1-Year Est. Return
MCL
MIK Capital LP New York $247M AUM 78.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

David M. Knott's Q2 2021 Portfolio in Review

As of Q2 2021, David M. Knott held 164 positions worth $281M, up 20% from $234M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

David M. Knott deployed $23.4M of net new capital in Q2 2021, opening 35 new positions and adding to 26 existing holdings. Its largest new stake was Coliseum Acquisition Corp. Unit: 1,485,000 shares worth $14.7M.

By sector, the portfolio is most concentrated in Financials at 28% of assets, up from 23% a quarter earlier, followed by Healthcare and Miscellaneous.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2.37M trimmed.

  • David M. Knott's largest Q2 2021 buy was Coliseum Acquisition Corp. Unit: 1,485,000 shares worth $14.7M.
  • David M. Knott added most to Calumet Specialty Products in Q2 2021, an estimated $1.9M increase.
  • David M. Knott's biggest Q2 2021 reduction was Gilead Sciences, cutting an estimated $2.37M.
  • David M. Knott fully exited African Gold Acquisition Corp Units in Q2 2021, selling an estimated $6.11M.
  • David M. Knott's ten largest holdings make up 46% of its $281M portfolio in Q2 2021.
  • David M. Knott opened 35 new positions and closed 17 in Q2 2021.
  • David M. Knott's portfolio value rose 20% quarter-over-quarter to $281M.

Based on David M. Knott's 13F filing for Q2 2021, filed 13 Aug 2021.